Method for preparing drug-loaded neutrophil

By co-incubating neutrophils with a buffer solution containing nicotinamide, Q-VD-Oph, and vitamin C, the problem of easy activation of liposomal drugs loaded on neutrophils in vitro was solved, achieving efficient drug delivery and long-term in vivo survival, thus improving drug loading efficiency and efficacy.

WO2025241581A1 Publication Date: 2025-11-27RAY MEDICINE BIOTECHNOLOGY CO LTD
7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/073906
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-24
Filing Date
2025-01-22
Publication Date
2025-11-27

AI Technical Summary

Technical Problem

Existing neutrophil-loaded liposome drug delivery methods are easily activated in vitro, leading to apoptosis and reduced drug loading efficiency, which prevents them from effectively crossing biological barriers and affects the survival time and efficacy of drugs in vivo.

Method used

Neutrophils were co-incubated with a buffer containing nicotinamide, Q-VD-Oph, and vitamin C. The drug was loaded into the cells through receptor-mediated endocytosis and phagocytosis, forming a drug-loaded neutrophil preparation.

Benefits of technology

It significantly reduces the apoptosis rate and activation level of neutrophils, improves drug loading efficiency and chemotactic efficiency, prolongs the survival time of drugs in vivo, and increases the concentration and efficacy of drugs at the disease site.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided in the present invention is a method for preparing a drug-loaded neutrophil. The method comprises the step of co-incubating, in a buffer containing nicotinamide, Q-VD-Oph and vitamin C, a neutrophil and a drug to be loaded. Further provided in the present invention are a drug-loaded neutrophil prepared using the method, and the use of the neutrophil in the preparation of a drug. The method provided in the present invention can significantly reduce the apoptosis ratio of neutrophils, reduce the in-vitro activation level of neutrophils, improve neutrophil viability and chemotactic efficiency under inflammatory conditions, and also improve the drug-loading efficiency of neutrophils, thereby realizing the efficient release of a drug at a disease site, and further improving the in-vivo survival time and efficacy of the drug.
Need to check novelty before this filing date? Find Prior Art